FrançaisAre analysts right about Hims & Hers Health (HIMS)?
📈 See the interactive version (live chart) →
Historical analyst accuracy
For Hims & Hers Health, we replayed every analyst price target of the past 12 months and measured the real outcome: 64% were profitable, average return +56% (56 calls). At 3 months: -2% average return (43% profitable). The higher the %, the more often analysts were right on this stock.
Most reliable analysts on this stock (past track record)
Their past track record on this stock (targets replayed against real prices) — not a forecast of what will happen.
| Analyst / broker | Calls i | % profitable i | Avg return i |
|---|---|---|---|
| B of A Securities | 13 | 92% | +75% |
| Citigroup | 10 | 60% | +49% |
| Canaccord Genuity | 5 | 80% | +77% |
| Needham | 5 | 40% | +10% |
Frequently asked questions
Is Hims & Hers Health a buy right now?
The analyst consensus on Hims & Hers Health (HIMS) is "Hold" (14 bullish, 4 bearish calls over 12 months). This is not advice: historically, 64% of their targets on this stock turned out profitable over 1 year.
What is Hims & Hers Health's price target?
The median 12-month price target is $32.00 (+1% vs $31.66), ranging from $25.00 to $42.00 (11 analysts).
Are analysts accurate on Hims & Hers Health?
Over 1 year, 64% of analyst targets on Hims & Hers Health were profitable, for an average return of +56% (across 56 timestamped calls). This is JPI Invest's accuracy metric.
What is the Hims & Hers Health stock forecast?
Analysts target a median of $32.00 within 12 months, i.e. +1% vs the current price. The most bullish targets $42.00, the most cautious $25.00.
What is the Hims & Hers Health stock forecast for 2026 or long term (2030)?
Note: analyst targets are 12-month (median $32.00, +1%), NOT 2030. No reliable 5-10 year price forecast exists (« 2030 prediction » models are speculative). The most useful inputs: the 12-month median above, these analysts' historical accuracy (64%), and the stock's past trajectory.
Is Hims & Hers Health overvalued?
Detailed valuation data for Hims & Hers Health is available in the interactive analysis.
📊 See the full interactive analysis of Hims & Hers Health →
What is JPI Invest?
JPI Invest aggregates analyst recommendations across the entire S&P 500 (plus the S&P MidCap 400), replays them against real prices and measures who predicts best — on results, not reputation. Instead of taking a price target at face value, you see each analyst's track record on each stock.
- 🏆 Analyst leaderboard by real reliability (beating their sector, not just riding the rally)
- 🎯 What to buy: 3 backtested methods over 6 years, from cautious to aggressive
- 💬 AI assistant: ask anything about any stock, with the numbers
- 📊 Portfolio tracking + 🔔 price alerts by email
⚠️ Educational information, not investment advice. Analyst price targets are 12-month and can be wrong. Data via Yahoo Finance, recomputed by JPI Invest.